News
Enara Bio announces the appointment of T-cell therapy leader
Dr. Sophie Papa as Chief Medical Officer
Dr. Papa joins Enara Bio from King’s College London (KCL) and Guy’s and St Thomas’ NHS Foundation Trust (GSTFT) where she was a Clinical Reader in Immuno-oncology and Consultant Medical Oncologist.
Enara Bio and Collaborators Present Progress Towards Developing MR1-targeted T-Cell Therapies at 12th International CD1-MR1 EMBO Meeting
Enara Bio announces the appointment of highly experienced biotech executive Dr. Robert Ang to its Board of Directors
Enara Bio announces the appointment of Dr. Robert Ang to the Company’s Board of Directors as an independent non-executive director
Enara Bio participates in Boehringer Ingelheim’s
“Taking Cancer On” podcast series
Enara Bio is pleased to have participated in Boehringer Ingelheim’s “Taking Cancer On” podcast series, launched today.
Enara Bio to present progress of research on novel, cancer-specific, MR1-restricted TCRs at upcoming TCR-based Therapies Summit
Dr. Rachel Abbott, Head of TCR Pipeline and Dark Antigen Research at Enara Bio, will present at the 2nd TCR-based Therapies Summit on 9 June.
Enara Bio adds further cell therapy and TCR expertise to its Senior Research Team
Dr Mark Creighton-Gutteridge appointed as Vice President, Head of Research
Dr Rachel Abbott appointed as Head of TCR Pipeline and Dark Antigen Research
Boehringer Ingelheim and Enara Bio enter Strategic Collaboration and Licensing Agreement to discover novel shared antigens for cancer immunotherapies
Collaboration focuses on up to three types of lung and gastrointestinal (GI) cancers. Latest in a series of strategic acquisitions and partnerships that strengthens Boehringer Ingelheim’s position in the cancer vaccine and T-cell engager spaces. Agreement and partnership with Boehringer Ingelheim provides additional validation of Enara Bio’s EDAPT™ platform and Dark Antigen™ discovery work and supports ongoing cell therapy based therapeutic approach.
Enara Bio adds further world-class cell therapy and immuno-oncology expertise to Senior Management Team and Scientific Advisory Board
Dr Erik Rutjens appointed as Vice President, Cell Therapy Operations
Dr Sadik Kassim and Dr Michael Quigley strengthen Scientific Advisory Board with deep industry experience
Enara Bio relocates to The Oxford Science Park’s newest facility to expand R&D capabilities in the search for novel cancer immunotherapies
Enara’s move from the Oxford BioEscalator to one of the UK's largest biomedical innovation centres is in preparation for its future growth and ambition to transform cancer care. The dedicated research facility will enable the company to accelerate the preclinical development of its lead MR1-targeting T-cell therapy program.
Enara Bio to present progress in Dark Antigen™ research at upcoming Neoantigen-Based Therapies Summit
Enara Bio, a biotechnology company leveraging its proprietary T-cell/T-cell receptor (TCR) discovery and Dark Antigen™ platforms to deliver targeted cancer immunotherapies, will present at the 5th Neoantigen Based Therapies Summit on November 5.